Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4605373 | 0.83 | TSHR (0.40) | TSHRCA1CA2 | |
| SCHEMBL3051880 | 0.82 | CA1 (0.34) | TSHRMMP2MMP9MMP12MMP14 | |
| SCHEMBL4478311 | 0.80 | FABP5 (0.36) | TSHRMMP2MMP9MMP12MMP14 | |
| SCHEMBL4606087 | 0.80 | HRH3 (0.32) | TSHRMMP2MMP9MMP12MMP14 | |
| SCHEMBL5140755 | 0.70 | CA1 (0.37) | CA1CA2 | |
| SCHEMBL6206197 | 0.67 | TSHR (0.48) | TSHR | |
| SCHEMBL3165966 | 0.65 | TTR (0.35) | TSHRCA1CA2 | |
| SCHEMBL472820 | 0.65 | TSHR (0.41) | TSHRCA1CA2 | |
| SCHEMBL334888 | 0.65 | TSHR (0.40) | TSHR | |
| SCHEMBL1279956 | 0.64 | TSHR (0.40) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337270-B1 | LONG-ACTING INTERFERON AND INTERLUKIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RES & DEV (IL) | 2008-07-16 | — | — | EP | disclosed |
| EP-1337270-A4 | LONG-ACTING CYTOKINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RES & DEV (IL) | 2005-09-14 | — | — | EP | disclosed |
| US-20040131586-A1 | Long-acting cytokine derivatives and pharmaceutical compositions comprising them | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-07-08 | — | — | US | disclosed |
| EP-1337270-A2 | LONG-ACTING CYTOKINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002036067-A2 | LONG-ACTING CYTOKINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040131586-A1 | Long-acting cytokine derivatives and pharmaceutical compositions comprising them | IL2, IFNG, CSF3R | TSHR 2729/4885MMP2 764/4885MMP9 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.